Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact


Christensen, H; Hickman, M; Edmunds, WJ; Trotter, CL; (2013) Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine, 31 (23). pp. 2638-2646. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2013.03.034

[img]
Preview
Text - Published Version
License:

Download (1MB) | Preview

Abstract

Background: Meningococcal disease remains an important cause of morbidity and mortality worldwide. The first broadly effective vaccine against group B disease (which causes considerable meningococcal disease in Europe, the Americas and Australasia) was licensed in the EU in January 2013; our objective was to estimate the potential impact of introducing such a vaccine in England. Methods: We developed two models to estimate the impact of introducing a new 'MenB' vaccine. The cohort model assumes the vaccine protects against disease only; the transmission dynamic model also allows the vaccine to protect against carriage (accounting for herd effects). We used these, and economic models, to estimate the case reduction and cost-effectiveness of a number of different vaccine strategies. Results: We estimate 27% of meningococcal disease cases could be prevented over the lifetime of an English birth cohort by vaccinating infants at 2,3,4 and 12 months of age with a vaccine that prevents disease only; this strategy could be cost-effective at 9 pound per vaccine dose. Substantial reductions in disease (71%) can be produced after 10 years by routinely vaccinating infants in combination with a large-scale catch-up campaign, using a vaccine which protects against carriage as well as disease; this could be cost-effective at 17 pound per vaccine dose. Conclusions: New 'MenB' vaccines could substantially reduce disease in England and be cost-effective if competitively priced, particularly if the vaccines can prevent carriage as well as disease. These results are relevant to other countries, with a similar epidemiology to England, considering the introduction of a new 'MenB' vaccine. (c) 2013 Elsevier Ltd. All rights reserved.

Item Type: Article
Keywords: Meningococcal, Vaccine, Model, Cost-effectiveness, neisseria-meningitidis, cost-effectiveness, randomized-trials, social, contacts, immunogenicity, dynamics, vaccines, multicomponent, metaanalysis, carriage
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 23566946
Web of Science ID: 320976800009
URI: http://researchonline.lshtm.ac.uk/id/eprint/1229325

Statistics


Download activity - last 12 months
Downloads since deposit
304Downloads
302Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item